184 related articles for article (PubMed ID: 35976133)
1. Chronological improvement in precision oncology implementation in Japan.
Sunami K; Naito Y; Komine K; Amano T; Ennishi D; Imai M; Kage H; Kanai M; Kenmotsu H; Koyama T; Maeda T; Morita S; Sakai D; Kohsaka S; Tsuchihara K; Saigusa Y; Yoshino T
Cancer Sci; 2022 Nov; 113(11):3995-4000. PubMed ID: 35976133
[TBL] [Abstract][Full Text] [Related]
2. The initial assessment of expert panel performance in core hospitals for cancer genomic medicine in Japan.
Sunami K; Naito Y; Aimono E; Amano T; Ennishi D; Kage H; Kanai M; Komine K; Koyama T; Maeda T; Morita S; Sakai D; Kohsaka S; Tsuchihara K; Yoshino T
Int J Clin Oncol; 2021 Mar; 26(3):443-449. PubMed ID: 33385275
[TBL] [Abstract][Full Text] [Related]
3. Effect of a Collaboration Between a Health Plan, Oncology Practice, and Comprehensive Genomic Profiling Company from the Payer Perspective.
Reitsma M; Fox J; Borre PV; Cavanaugh M; Chudnovsky Y; Erlich RL; Gribbin TE; Anhorn R
J Manag Care Spec Pharm; 2019 May; 25(5):601-611. PubMed ID: 30632889
[TBL] [Abstract][Full Text] [Related]
4. [Current Status and Prospects of the Comprehensive Cancer Genome Profiling].
Imoto I; Fukue M; Takaiso N
Gan To Kagaku Ryoho; 2021 Jan; 48(1):7-11. PubMed ID: 33468714
[TBL] [Abstract][Full Text] [Related]
5. Identification of barriers to implementation of precision oncology in patients with rare cancers.
Takamizawa S; Koyama T; Sunami K; Sudo K; Hirata M; Kubo T; Tao K; Cho H; Narita Y; Kato K; Yamazaki N; Ohe Y; Okusaka T; Matsui Y; Ogawa C; Yonemori K; Yamamoto N
Cancer Sci; 2024 Jun; 115(6):2023-2035. PubMed ID: 38538548
[TBL] [Abstract][Full Text] [Related]
6. Current Clinical Practice of Precision Medicine Using Comprehensive Genomic Profiling Tests in Biliary Tract Cancer in Japan.
Kanai M
Curr Oncol; 2022 Sep; 29(10):7272-7284. PubMed ID: 36290850
[TBL] [Abstract][Full Text] [Related]
7. The impact of rare cancer and early-line treatments on the benefit of comprehensive genome profiling-based precision oncology.
Kubo T; Sunami K; Koyama T; Kitami M; Fujiwara Y; Kondo S; Yonemori K; Noguchi E; Morizane C; Goto Y; Maejima A; Iwasa S; Hamaguchi T; Kawai A; Namikawa K; Arakawa A; Sugiyama M; Ohno M; Yoshida T; Hiraoka N; Yoshida A; Yoshida M; Nishino T; Furukawa E; Narushima D; Nagai M; Kato M; Ichikawa H; Fujiwara Y; Kohno T; Yamamoto N
ESMO Open; 2024 Apr; 9(4):102981. PubMed ID: 38613908
[TBL] [Abstract][Full Text] [Related]
8. First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy Opportunities.
Matsubara J; Mukai K; Kondo T; Yoshioka M; Kage H; Oda K; Kudo R; Ikeda S; Ebi H; Muro K; Hayashi R; Tokudome N; Yamamoto N; Muto M
JAMA Netw Open; 2023 Jul; 6(7):e2323336. PubMed ID: 37459099
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility of Todai OncoPanel in the setting of approved comprehensive cancer genomic profiling tests in Japan.
Kage H; Shinozaki-Ushiku A; Ishigaki K; Sato Y; Tanabe M; Tanaka S; Tanikawa M; Watanabe K; Kato S; Akagi K; Uchino K; Mitani K; Takahashi S; Miura Y; Ikeda S; Kojima Y; Watanabe K; Mochizuki H; Yamaguchi H; Kawazoe Y; Kashiwabara K; Kohsaka S; Tatsuno K; Ushiku T; Ohe K; Yatomi Y; Seto Y; Aburatani H; Mano H; Miyagawa K; Oda K
Cancer Sci; 2023 Apr; 114(4):1710-1717. PubMed ID: 36601953
[TBL] [Abstract][Full Text] [Related]
10. [From the Standpoint of a Core Center Hospital for Cancer Genome Medicine-Establishment of a Provision System for Wide-Area Precision Oncology].
Muto M; Kondo T; Yoshioka M; Fukuyama K; Suga J; Sato M; Masuda F; Ashida K; Mukai K; Matsumoto S; Kanai M
Gan To Kagaku Ryoho; 2021 Jul; 48(7):866-872. PubMed ID: 34267018
[TBL] [Abstract][Full Text] [Related]
11. Establishment and implementation of Cancer Genomic Medicine in Japan.
Mukai Y; Ueno H
Cancer Sci; 2021 Mar; 112(3):970-977. PubMed ID: 33289217
[TBL] [Abstract][Full Text] [Related]
12. Utility of Precision Oncology Using Cancer Genomic Profiling for Head and Neck Malignancies.
Matsuo M; Hashimoto K; Kogo R; Jiromaru R; Hongo T; Manako T; Nakagawa T
In Vivo; 2023; 37(5):2147-2154. PubMed ID: 37652518
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice.
Ida H; Koyama T; Mizuno T; Sunami K; Kubo T; Sudo K; Tao K; Hirata M; Yonemori K; Kato K; Okusaka T; Ohe Y; Matsui Y; Yamazaki N; Ogawa C; Kawai A; Narita Y; Esaki M; Yamamoto N
Cancer Sci; 2022 Dec; 113(12):4300-4310. PubMed ID: 36106376
[TBL] [Abstract][Full Text] [Related]
14. Travel Time and Distance and Participation in Precision Oncology Trials at the National Cancer Center Hospital.
Uehara Y; Koyama T; Katsuya Y; Sato J; Sudo K; Kondo S; Yoshida T; Shoji H; Shimoi T; Yonemori K; Yamamoto N
JAMA Netw Open; 2023 Sep; 6(9):e2333188. PubMed ID: 37713200
[TBL] [Abstract][Full Text] [Related]
15. Concordance Between Recommendations From Multidisciplinary Molecular Tumor Boards and Central Consensus for Cancer Treatment in Japan.
Naito Y; Sunami K; Kage H; Komine K; Amano T; Imai M; Koyama T; Ennishi D; Kanai M; Kenmotsu H; Maeda T; Morita S; Sakai D; Watanabe K; Shirota H; Kinoshita I; Yoshioka M; Mamesaya N; Ito M; Kohsaka S; Saigusa Y; Yamamoto K; Hirata M; Tsuchihara K; Yoshino T
JAMA Netw Open; 2022 Dec; 5(12):e2245081. PubMed ID: 36469316
[TBL] [Abstract][Full Text] [Related]
16. The molecular tumor board: a tool for the governance of precision oncology in the real world.
Incorvaia L; Russo A; Cinieri S
Tumori; 2022 Aug; 108(4):288-290. PubMed ID: 34918610
[TBL] [Abstract][Full Text] [Related]
17. Impact of a Clinical Genomics Program on Trial Accrual for Targeted Treatments: Practical Approach Overcoming Barriers to Accrual for Underserved Patients.
Farhangfar CJ; Scarola GT; Morris VA; Farhangfar F; Dumas K; Symanowski J; Hwang JJ; Mileham KF; Carrizosa DR; Naumann RW; Livasy C; Kim ES; Raghavan D
JCO Clin Cancer Inform; 2022 Jul; 6():e2200011. PubMed ID: 35839431
[TBL] [Abstract][Full Text] [Related]
18. Human resources for administrative work to carry out a comprehensive genomic profiling test in Japan.
Kage H; Oda K; Muto M; Tsuchihara K; Okita N; Okuma Y; Kikuchi J; Shirota H; Hayashi H; Kokuryo T; Sakai D; Hirasawa A; Kubo M; Kenmotsu H; Akiyama N; Shinozaki-Ushiku A; Tanabe M; Ushiku T; Miyagawa K; Seto Y
Cancer Sci; 2023 Jul; 114(7):3041-3049. PubMed ID: 37165760
[TBL] [Abstract][Full Text] [Related]
19. Implementation and Outcomes of a Molecular Tumor Board at Herbert-Herman Cancer Center, Sparrow Hospital.
Trivedi H; Acharya D; Chamarthy U; Meunier J; Ali-Ahmad H; Hamdan M; Herman J; Srkalovic G
Acta Med Acad; 2019 Apr; 48(1):105-115. PubMed ID: 31264438
[TBL] [Abstract][Full Text] [Related]
20. Patient survey on cancer genomic medicine in Japan under the national health insurance system.
Kage H; Akiyama N; Chang H; Shinozaki-Ushiku A; Ka M; Kawata J; Muto M; Okuma Y; Okita N; Tsuchihara K; Kikuchi J; Shirota H; Hayashi H; Kokuryo T; Yachida S; Hirasawa A; Kubo M; Kenmotsu H; Tanabe M; Ushiku T; Muto K; Seto Y; Oda K
Cancer Sci; 2024 Mar; 115(3):954-962. PubMed ID: 38273803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
